Speaker Profile
MD, Professor in Cancer Biology, UCSF
Biography
Lawrence Fong, M.D., the Efim Guzik Distinguished Professor in Cancer Biology, is the founding director of the Cancer Immunotherapy Program at the Helen Diller Family Comprehensive Cancer, University of California, San Francisco. He also co-directs the Parker Institute of Cancer Immunotherapy at UCSF. He received a B.A. in economics from Columbia University and a M.D. from Stanford University. He completed internal medicine and oncology subspecialty training at University of Washington and Stanford University, respectively. Dr. Fong has been involved in both pre-clinical and clinical studies of multiple cancer immunotherapies including anti-CTLA-4 and anti-PD-(L)1 antibodies that are now FDA-approved. His laboratory examines the mechanisms that underlie clinical response and resistance to the different immunotherapies. He has co-authored of >100 manuscripts. Dr. Fong is the recipient NIH Outstanding Investigator Award.
Session Abstract – PMWC 2024 Silicon Valley
Track Chair: Sharon Benzeno, Adaptive Biotechnologies
- PMWC 2024 Award Ceremony
Pioneer Honoree: Stanley Riddell, Fred Hutchinson
Pioneer Honoree: George Coukos, Ludwig Cancer Center
- Keynote: Engineering Synthetic T Cell States for Cancer Rejection
- George Coukos, Ludwig Cancer Center
- Discovery of Novel Targets in Cell Therapies in Oncology and Autoimmune Disorders (PANEL)
Chair: Harlan Robins, Adaptive Bio
- Stanley Riddell, Fred Hutchinson
- Allison Betof Warner, Stanford
- Lawrence Fong, UCSF - Supply Chain 2.0 Getting Cell Therapies to Patients (PANEL)
Chair: Jean Xu, Janssen Pharmaceuticals
- Amanda Pace, Sonoma Bio
- Laura Deschenes, Sana Biotechnology - Evolving Case Law and Practical Strategies for Immunotherapy Patents
- Janet Xiao, Morrison & Foerster LLP
- Emerging Clinical Data in Oncology Cell Therapeutics
Chair: Andrew Allen, Gritstone bio, Inc.
- Robert Meehan, Moderna - Scientific Advancements in Individualized Cell Therapies in Oncology ( PANEL)
Chair: Sharon Benzeno, Adaptive Biotechnologies
- Ira Mellman, Genenetch
- Robert Meehan, Moderna
- Dirk Nagorsen, Affini-T Therapeutics - AI-Enhanced Approaches in Cell Therapy Development
Chair: Suchit Jhunjhunwala, Genentech
- Brian Weitzner, Outpace Bio
- PMWC Showcase
- Arun Wiita, UCSF
